Login to Your Account



Pharma: Other News To Note


Monday, February 25, 2013
• Lupin Ltd., of Mumbai, India, said its subsidiary, Lupin Pharmaceuticals Inc., received approval for Suprax (cefixime) for oral suspension, 500 mg/5mL from the FDA. The approval will expand Lupin's range of Suprax dosage forms available to treat approved indications in appropriate patients.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription